3 small-cap biotechs with potential breakthroughs in 2024

Key PointsAmylyx may get its flagship treatment for ALS approved by the European Medicines Agency (EMA), opening another avenue for revenue growth.  Puma Biotechnology will begin a mid-stage trial for its lead cancer drug.  Cassava Sciences forecasts top-line results for a Phase 3 study on its Alzheimer's disease drug to be available by the end of the calendar year.  5 stocks we like better than Amylyx PharmaceuticalsThere's a reason that many biotech investors prefer to stick with large-cap stocks. Investi ...